慢性阻塞性肺病患者的肺康复和内皮功能:一个前性队列研究
Pasquale Ambrosino1, Matteo Nicola Dario Di Minno2, Silvestro Ennio D'Anna3
1Istituti Clinici Scientifici Maugeri IRCCS, Directorate of Telese Terme Institute, Italy.
European journal of internal medicine
|June 22, 2023
概括
肺部康复在慢性阻塞性肺病 (COPD) 患者中显著改善内皮功能,增强流媒扩张 (FMD),并可能降低心血管风险. 这种改善与更好的肺功能有关.
科学领域:
- 心脏病学 心脏病学
- 肺部病理学 肺部病理学
- 血管生物学 血管生物学
背景情况:
- 慢性阻塞性肺病 (COPD) 与内皮功能障碍和心血管风险增加有关.
- 亚临床动脉样硬化是COPD患者已知的并发症.
研究的目的:
- 评估在接受肺康复的重症慢性肺炎患者内皮依赖流媒扩张 (FMD) 的变化.
- 评估肺部康复对COPD血管功能的影响.
主要方法:
- 包括连续COPD患者入住肺部康复病房.
- 在入院和出院时测量口病.
- 功能参数,运动能力和生活质量的分析.
主要成果:
- 肺部康复导致中位数口炎显著增加52.3% (从3.25%增加到4.95%,P<0.001).
- 在功能参数,运动能力和生活质量方面观察到改善.
- 增加的口病与1秒内强迫呼气体积 (FEV1) 和预测的FEV1百分比的改善有关.
结论:
- 肺部康复可以改善COPD患者的内皮功能.
- 这些发现表明,降低心血管风险的潜在好处值得进一步研究.
- 肺功能改善 (FEV1) 独立预测康复后内皮功能增强.
相关概念视频
Chronic Obstructive Pulmonary Disease-V: Management
2.6K
Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
Smoking Cessation
2.6K
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
204
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
204
Chronic Obstructive Pulmonary Disease-II: Pathophysiology
2.9K
Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation
Chronic Inflammation
2.9K
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
221
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
221
Chronic Obstructive Pulmonary Disease-I: Introduction
2.8K
Chronic Obstructive Pulmonary Disease (COPD) is a long-lasting respiratory condition requiring continuous attention and care. It is a progressive lung disease that leads to breathing challenges due to airflow obstruction. It manifests as persistent respiratory symptoms and restricted airflow resulting from abnormalities in the airways and alveoli, usually due to long-term exposure to harmful particles or gases. COPD mainly consists of two primary conditions: emphysema and chronic bronchitis.
2.8K
Chronic Obstructive Pulmonary Disease-III: Symptoms and Complications.
2.8K
Understanding the variety of primary symptoms and systemic complications that characterize chronic obstructive pulmonary disease (COPD) is crucial for healthcare professionals.
Symptoms of COPD can be classified as primary or systemic. Primary symptoms relate to reduced airflow, while systemic or extrapulmonary symptoms relate to COPD's broader impact on the body.
Primary Symptoms of COPD:
Symptoms of COPD can be classified as primary or systemic. Primary symptoms relate to reduced airflow, while systemic or extrapulmonary symptoms relate to COPD's broader impact on the body.
Primary Symptoms of COPD:
2.8K


